What is the significance of Amendment No. 4 to the Collaboration Agreement?

Amendment No. 4 to the Collaboration Agreement, entered into with sanofi-aventis U.S., LLC, grants both Regeneron and sanofi-aventis a royalty-free, non-exclusive license to intellectual property that is directly discovered through the research and development activities conducted under the collaboration. This provides clarity on IP ownership and usage rights moving forward.

What is VEGF Trap-Eye and why is it important?

VEGF Trap-Eye is an investigational drug formulation being studied by Regeneron for the treatment of neovascular age-related macular degeneration (AMD). AMD is a leading cause of vision loss in older adults, and a successful treatment could represent a significant commercial opportunity. The preliminary results from the Phase 1 study are an early indication of the drug's potential.

What kind of results were announced for VEGF Trap-Eye?

The press release, furnished as Exhibit 99.1, announced preliminary results from an ongoing Phase 1 dose-escalation study. While specific details of the results are not provided in the 8-K itself, the announcement indicates that Regeneron is moving forward with the clinical development of VEGF Trap-Eye.

REGN 8-K: Material Agreements

Summary

Regeneron Pharmaceuticals, Inc. (REGN) filed an 8-K on February 3, 2006, primarily to disclose two key events. First, the company entered into Amendment No. 4 to its Collaboration Agreement with sanofi-aventis U.S., LLC, effective February 1, 2006. This amendment grants each party a royalty-free, non-exclusive license to intellectual property discovered during the collaboration. Second, Regeneron issued a press release on February 2, 2006, detailing preliminary results from a Phase 1 study of its VEGF Trap-Eye formulation in patients with neovascular age-related macular degeneration (AMD). This development is significant as it signals progress in the clinical evaluation of a potentially important drug candidate for a major ophthalmic disease.

Key Highlights

1Regeneron amended its Collaboration Agreement with sanofi-aventis U.S., LLC, effective February 1, 2006.
2The amendment grants each party a royalty-free, non-exclusive license to intellectual property arising from the collaboration.
3Regeneron announced preliminary results from a Phase 1 study of VEGF Trap-Eye on February 2, 2006.
4The Phase 1 study is evaluating VEGF Trap-Eye in patients with neovascular age-related macular degeneration (AMD).
5This 8-K filing includes a furnished press release detailing the Phase 1 study results (Exhibit 99.1).

REGENERON PHARMACEUTICALS, INC. 8-K Report, Material Agreement (Feb 3, 2006)

Summary

Key Highlights

Frequently Asked Questions